Scarica l'app Stockscreener
2.03
6.28%
0.12
Dopo l'orario di chiusura:
2.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMEA Giù?
Forum
Previsione
Biomea Fusion Inc Borsa (BMEA) Ultime notizie
After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright - Yahoo Finance
Biomea Fusion Completes Key Phase 2 Trial in Type 1 Diabetes: What Investors Should Watch Next - TipRanks
Biomea Fusion to Participate in Upcoming Investor Conferences - Investing News Network
BMEA Surges 6.85%: Biomea Fusion Approaches Key $1.88 ResistanceQuote Data - vinanet.vn
BMEA Should I Buy - Intellectia AI
Biomea Fusion Inc (BMEA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Biomea Shares Rise After Completing Enrollment in Diabetes Trial - marketscreener.com
Biomea Fusion stock surges on diabetes trial enrollment completion By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Biomea Fusion stock rating on trial enrollment By Investing.com - Investing.com UK
Why is Biomea Fusion stock climbing today? By Investing.com - Investing.com India
Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes - TradingView
Biomea Fusion completes enrollment in diabetes trial By Investing.com - Investing.com UK
Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it? - TradingView
Biomea Fusion completes enrollment in diabetes trial - Investing.com
Biomea (BMEA) Quarterly Results: Profit Per Share Clears Its Benchmark at the Close; Investor Response - vinanet.vn
Biomea Fusion begins dosing first participant in OPAL study arm for new combination therapy - Traders Union
Biomea Fusion (NASDAQ:BMEA) Gains Attention As Institutions Expand Exposure - Kalkine Media
Biomea Fusion shares new insights on three stages of type 1 diabetes in expert webinar - Traders Union
Biomea Fusion doses first patient in icovamenib-semaglutide study By Investing.com - Investing.com Canada
Biomea Fusion doses first patient in icovamenib-semaglutide study - Investing.com
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity - The Manila Times
Biomea Fusion Initiates OPAL Study Arm of Icovamenib Plus Low-Dose Semaglutide in Obesity Research - Quiver Quantitative
Biomea Fusion Trial Tests Obesity Drug Combo Beyond Weight Loss - Stock Titan
Renaissance Technologies LLC Grows Position in Biomea Fusion, Inc. $BMEA - MarketBeat
Biomea Fusion Inc (BMEA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BMEA Q2 2026 Earnings: Narrower Loss Delivers 47% EPS Surprise as Pipeline Progress ContinuesEarnings Outlook Update - vinanet.vn
HC Wainwright Expects Stronger Earnings for Biomea Fusion - MarketBeat
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Biomea Fusion Stock (BMEA) Opinions on Clinical Milestones and Liquidity Concerns - Quiver Quantitative
Icovamenib clinical enrollment opens for type 2 diabetes study, Biomea Fusion initiates - Traders Union
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Citizens JMP Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
Biomea Fusion Inc (BMEA) Stock News Today - TradingKey
Biomea Fusion explores new scientific approaches to diabetes treatment - Traders Union
Oppenheimer Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Biomea Fusion (BMEA) Edges Higher: Bounces Off Support as Oversold Conditions EaseIndex Put Call - dars.gov.et
Biomea Fusion, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Biomea Fusion (NASDAQ:BMEA) Issues Earnings Results - MarketBeat
Biomea Fusion Q2 loss narrows, cash runway into Q2 2027 - TradingView
Biomea Fusion (NASDAQ: BMEA) trims R&D, discloses going concern risk - Stock Titan
Biomea Fusion, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights - Yahoo Finance
Biomea Fusion (BMEA) Gains 2.56% to $1.2 as Key Levels Come into FocusStock Surge Alerts - dars.gov.et
Participants sought for type 2 diabetes trial evaluating icovamenib, Biomea Fusion announces - Traders Union
Biomea Fusion Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
BMEA Q2'26 Earnings: EPS estimate is (0.22) USD - tradingview.com
Biomea Fusion (BMEA) Nears Key Support as Selling Pressure ContinuesMA Crossover - vinanet.vn
Biomea Fusion (BMEA) to Post Earnings on Tuesday - MarketBeat
Biomea Fusion Inc (BMEA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biomea Fusion Inc (BMEA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BMEA|Biomea Fusion Inc|Price:1.250|Chg%:-0.010 - TradingKey
Biomea Fusion Inc (BMEA) Balance Sheet - TradingKey
Biomea Fusion Inc (BMEA) Income Statement - TradingKey
Biomea Fusion Inc (BMEA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Biomea Fusion Inc (BMEA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BMEA|Biomea Fusion Inc|Price:1.265|Chg%:+0.015 - TradingKey
BMEA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
TradingKey - TradingKey
Biomea Fusion Inc (BMEA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Biomea Fusion Inc (BMEA) Institutional Confidence - TradingKey
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):